Pfizer Takes Aim at Regeneron, and UnitedHealth's Earnings Update
Pfizer's latest phase 3 trial results put its promising eczema drug on a path to challenge Regeneron and Sanofi's $2 billion-per-year drug, Dupixent. Also, how Regenxbio (NASDAQ: RGNX) and Adverum Biotechnologies hope to change how a we treat a common cause of vision loss in seniors, and why United Healthcare's (NYSE: UNH) latest quarterly results sent shares soaring. Host Shannon Jones tackles these topics with contributor Todd Campbell on this edition of Industry Focus: Healthcare.
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.
Source Fool.com
